FDA遵循其肿瘤药物咨询委员会的建议,并发出了完整的回复函,拒绝批准131I-omburtamab用于治疗由神经母细胞瘤引起的中枢神经系统和软脑膜转移。——出国看病 根据Y-mAbs Therapeutics的新闻稿,131I-omburtamab是针对已发生中枢神经系统或软脑膜转移的神经母细胞瘤患者的潜在治疗方法,已获得FDA的完整回复函。——出国看...
06 Jan 2023Y-mAbs Therapeutics anticipates a Type A meeting with the US FDA to discuss potential regulatory pathway for omburtamab in January 2023 You need to be a logged in or subscribed to view this contentRequest demo If your organization or you do not have a subscription, try one of...